Neumora Therapeutics Inc
NASDAQ:NMRA

  • LAST PRICE
    11.7200
  • TODAY'S CHANGE (%)
    -1.9200 (-14.0762%)
  • Bid / Lots
    11.6800/ 8
  • Ask / Lots
    11.7300/ 3
  • Open / Previous Close
    13.0200 / 13.6400
  • Day Range
    11.4550
    13.0500
  • 52 Week Range
    8.3300
    21.0000
  • Volume
    694,242

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
NMRA
Neumora Therapeutics Inc
2.2B
-7.0x
---
GPCR
Structure Therapeutics Inc
2.2B
-16.3x
---
CNTA
Centessa Pharmaceuticals PLC
2.1B
-11.1x
---
AKRO
Akero Therapeutics Inc
2.3B
-9.5x
---
LBPH
Longboard Pharmaceuticals Inc
2.3B
-26.7x
---
NAMS
NewAmsterdam Pharma Company NV
2.3B
-10.9x
---
As of 2024-11-12

Company Information

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Contact Information

Headquarters
490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
Phone
857-760-0900
Fax
302-655-5049

Executives

Executive Chairman of the Board, Co-Founder
Paul Berns
President, Chief Executive Officer, Director
Henry Gosebruch
Co-Founder, Chief Operating Officer
Carol Suh
Chief Financial Officer
Joshua Pinto
Chief Strategy Officer
Daljit Aurora

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.2B
Revenue (TTM)
$0.00
Shares Outstanding
160.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.66
Book Value
$2.95
P/E Ratio
-7.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.